Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aldeyra Therapeutics, Inc.ALDX · Entity 6839 | Director | June 09, 2026 | June 11, 2026 |
| MAXCYTE, INC.MXCT · Entity 6608 | Director | June 17, 2026 | June 22, 2026 |
| NOVAVAX INCNVAX · Entity 4632 | Director | June 18, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aldeyra Therapeutics, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2036-06-08 | Direct | 70,000 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 70,000 · Balance 70,000 F1: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2036-06-08 | Direct | 19,909 |
Reported balance
After 2026-06-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-09 · Grant · Acquired 19,909 · Balance 19,909 F2: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as the Chairperson of the Board of Directors of the Issuer through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2036-06-08 | Direct | 2,323 |
Reported balance
After 2026-06-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-09 · Grant · Acquired 2,323 · Balance 2,323 F3: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date.
F2: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as the Chairperson of the Board of Directors of the Issuer through the applicable vesting date.
F3: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date.
MAXCYTE, INC.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 260,998 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 30,421 · Balance 260,998 F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F2: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.13 · Expires 2036-06-16 | Direct | 49,579 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Grant · Acquired 49,579 · Balance 49,579 F2: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F2: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date.
NOVAVAX INC
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 73,220 |
Reported balance
After 2026-06-20 transaction · row 1
1 source rowRow 1 · 2026-06-20 · Exercise / conversion · Acquired 18,880 · Balance 73,220 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.13 · Expires 2036-06-18 | Direct | 21,270 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 21,270 · Balance 21,270 F2: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 14,180 |
Reported balance
After 2026-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-18 · Grant · Acquired 14,180 · Balance 14,180 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F3: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-20 · Exercise / conversion · Disposed 18,880 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F4: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F2: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
F3: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
F4: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 20, 2026 Filed Jun 23, 2026 23:56 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 18,880 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-076927 · tm2618639-6_4seq1.xml · derivative · entry 4 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,880 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F4 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date F4 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date Read SEC document |
| June 20, 2026 Filed Jun 23, 2026 23:56 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 18,880 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-076927 · tm2618639-6_4seq1.xml · nonDerivative · entry 1 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 23:56 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 14,180 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-076927 · tm2618639-6_4seq1.xml · derivative · entry 3 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,180 Underlying: Common Stock · 14,180 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F3 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. F3 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 23:56 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to Buy) · Derivative | 21,270 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0001104659-26-076927 · tm2618639-6_4seq1.xml · derivative · entry 2 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,270 Underlying: Common Stock · 21,270 shares Expires 2036-06-18 F2 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:26 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantStock Option (right to buy) · Derivative | 49,579 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0000905148-26-003053 · form4.xml · derivative · entry 2 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,579 Underlying: Common Stock · 49,579 shares Expires 2036-06-16 F2 · derivative.exercise_date: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:26 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantCommon Stock | 30,421 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-003053 · form4.xml · nonDerivative · entry 1 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,998 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F2 · shares: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 20:26 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 2,323 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001193125-26-267629 · ownership.xml · derivative · entry 3 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,323 Underlying: Common Stock · 2,323 shares Expires 2036-06-08 F3 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 20:26 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 19,909 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001193125-26-267629 · ownership.xml · derivative · entry 2 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,909 Underlying: Common Stock · 19,909 shares Expires 2036-06-08 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as the Chairperson of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 20:26 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001193125-26-267629 · ownership.xml · derivative · entry 1 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2036-06-08 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:17 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | PurchaseCommon Stock | 70,000 | $1.40 | $98,000.00 |
DisclosureSEC source: 0001193125-26-117675 · ownership.xml · nonDerivative · entry 1 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,000 Read SEC document |
| August 13, 2025 Filed Aug 13, 2025 23:46 UTC | MAXCYTE, INC. MXCT · Entity 6608 | PurchaseCommon Stock | 80,000 | $1.39 | $111,040.00 |
DisclosureSEC source: 0000905148-25-002874 · form4.xml · nonDerivative · entry 1 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,577 F1 · price: These shares were purchased in multiple transactions at prices ranging from $1.30 to $1.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 22:37 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 18,884 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-062193 · tm2518838-3_4seq1.xml · derivative · entry 2 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,884 Underlying: Common Stock · 18,884 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2024 grant date subject to continued service on the Company's Board of Directors through the vesting date. F2 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2024 grant date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 22:37 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to Buy) · Derivative | 28,326 | $6.42 Strike: $6.42 | $181,852.92 |
DisclosureSEC source: 0001104659-25-062193 · tm2518838-3_4seq1.xml · derivative · entry 1 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,326 Underlying: Common Stock · 28,326 shares Expires 2035-06-20 F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 20, 2024 grant date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 22:39 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantStock Option (right to buy) · Derivative | 50,790 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0000905148-25-002232 · form4.xml · derivative · entry 2 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,790 Underlying: Common Stock · 50,790 shares Expires 2035-06-17 F2 · derivative.exercise_date: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 18, 2026, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 22:39 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantCommon Stock | 29,210 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-002232 · form4.xml · nonDerivative · entry 1 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,577 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F2 · shares: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 18, 2026, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| June 12, 2025 Filed Jun 14, 2025 01:36 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 10,420 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001593968-25-000757 · primary_01.xml · derivative · entry 2 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,420 shares Expires 2034-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2025 Filed Jun 14, 2025 01:36 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 10,420 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-25-000757 · primary_01.xml · nonDerivative · entry 1 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:27 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 1,689 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0000950170-25-085441 · ownership.xml · derivative · entry 3 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,689 Underlying: Common Stock · 1,689 shares Expires 2035-06-09 F3 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:27 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 14,476 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0000950170-25-085441 · ownership.xml · derivative · entry 2 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,476 Underlying: Common Stock · 14,476 shares Expires 2035-06-09 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as the Chairperson of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:27 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 62,728 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0000950170-25-085441 · ownership.xml · derivative · entry 1 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,728 Underlying: Common Stock · 62,728 shares Expires 2035-06-09 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:10 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 10,420 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001593968-24-000863 · primary_01.xml · derivative · entry 4 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,420 Underlying: Common Stock · 10,420 shares Expires 2034-06-12 Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:10 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to Buy) · Derivative | 15,630 | $15.86 Strike: $15.86 | $247,891.80 |
DisclosureSEC source: 0001593968-24-000863 · primary_01.xml · derivative · entry 3 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,630 Underlying: Common Stock · 15,630 shares Expires 2034-06-12 Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:10 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 6,670 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001593968-24-000863 · primary_01.xml · derivative · entry 2 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,670 shares Expires 2033-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:10 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 6,670 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-24-000863 · primary_01.xml · nonDerivative · entry 1 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,920 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 21:39 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantStock Option (right to buy) · Derivative | 40,701 | $0.00 Strike: $4.68 | $0.00 |
DisclosureSEC source: 0001415889-24-016715 · form4-06132024_090638.xml · derivative · entry 2 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,701 Underlying: Common Stock · 40,701 shares Expires 2034-06-10 F2 · derivative.exercise_date: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 11, 2025, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 21:39 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantCommon Stock | 21,367 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-016715 · form4-06132024_090638.xml · nonDerivative · entry 1 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,367 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F2 · shares: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 11, 2025, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:15 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 1,215 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0000950170-24-069900 · ownership.xml · derivative · entry 3 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,215 Underlying: Common Stock · 1,215 shares Expires 2034-06-03 F3 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:15 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 10,418 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0000950170-24-069900 · ownership.xml · derivative · entry 2 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,418 Underlying: Common Stock · 10,418 shares Expires 2034-06-03 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as the Chairperson of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:15 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 40,282 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0000950170-24-069900 · ownership.xml · derivative · entry 1 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,282 Underlying: Common Stock · 40,282 shares Expires 2034-06-03 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 21:32 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 640 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0000950170-23-031778 · ownership.xml · derivative · entry 3 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 640 Underlying: Common Stock · 640 shares Expires 2033-06-29 F3 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 21:32 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 5,488 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0000950170-23-031778 · ownership.xml · derivative · entry 2 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,488 Underlying: Common Stock · 5,488 shares Expires 2033-06-29 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as the Chairperson of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 21:32 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 21,222 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0000950170-23-031778 · ownership.xml · derivative · entry 1 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,222 Underlying: Common Stock · 21,222 shares Expires 2033-06-29 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 22, 2023 Filed Jun 23, 2023 21:34 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0001209191-23-039477 · doc4.xml · derivative · entry 1 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: This annual option grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this option vest on June 22, 2024, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 20:44 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 6,670 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-036744 · doc4.xml · derivative · entry 4 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,670 Underlying: Common Stock · 6,670 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F4 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Plan will vest one (1) year from the Grant Date subject to continued service on the Company's Board of Directors through the vesting date. F4 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Plan will vest one (1) year from the Grant Date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 20:44 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to Buy) · Derivative | 7,710 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0001209191-23-036744 · doc4.xml · derivative · entry 3 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,710 Underlying: Common Stock · 7,710 shares Expires 2033-06-12 F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Plan will vest one (1) year from the June 12, 2023 grant date (the "Grant Date") subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 10, 2023 Filed Jun 13, 2023 20:44 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 3,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-036744 · doc4.xml · derivative · entry 2 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), vested on the first anniversary of the June 10, 2022 grant date subject to continued service on the Company's Board of Directors through the vesting date. F2 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), vested on the first anniversary of the June 10, 2022 grant date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 10, 2023 Filed Jun 13, 2023 20:44 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 3,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-036744 · doc4.xml · nonDerivative · entry 1 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. Read SEC document |
| March 29, 2023 Filed Mar 30, 2023 13:11 UTC | MAXCYTE, INC. MXCT · Entity 6608 | PurchaseCommon Stock | 80,000 | $4.32 | $345,480.00 |
DisclosureSEC source: 0001209191-23-021573 · doc4.xml · nonDerivative · entry 1 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 F1 · price: The Reporting Person purchased the securities on the open market at purchase prices ranging from $4.20 to $4.35 per share, with a weighted average purchase price of $4.3185 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| June 29, 2022 Filed Jul 8, 2022 20:05 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantStock Option (right to buy) · Derivative | 26,900 | $0.00 Strike: $4.82 | $0.00 |
DisclosureSEC source: 0001209191-22-041612 · doc4.xml · derivative · entry 1 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,900 Underlying: Common Stock · 26,900 shares Expires 2032-06-28 F1 · derivative.exercise_date: This annual option grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this option vest on June 29, 2023, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 00:46 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-038592 · doc4.xml · derivative · entry 2 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 17, 2021 grant date subject to continued service on the Company's Board of Directors through the vesting date. F2 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 17, 2021 grant date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 00:46 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-038592 · doc4.xml · nonDerivative · entry 1 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,150 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 21:07 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 3,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-036749 · doc4.xml · derivative · entry 2 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,100 Underlying: Common Stock · 3,100 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Company common stock. F3 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Plan will vest one (1) year from the Grant Date subject to continued service on the Company's Board of Directors through the vesting date. F3 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Plan will vest one (1) year from the Grant Date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 21:07 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to Buy) · Derivative | 4,600 | $0.00 Strike: $40.62 | $0.00 |
DisclosureSEC source: 0001209191-22-036749 · doc4.xml · derivative · entry 1 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,600 Underlying: Common Stock · 4,600 shares Expires 2032-06-10 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan") will vest one (1) year from the June 10, 2022 grant date (the "Grant Date") subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:06 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 1,624 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0000899243-22-021633 · doc4.xml · derivative · entry 3 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,624 Underlying: Common Stock · 1,624 shares Expires 2032-06-06 F3 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:06 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 13,917 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0000899243-22-021633 · doc4.xml · derivative · entry 2 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,917 Underlying: Common Stock · 13,917 shares Expires 2032-06-06 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as the Chairperson of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:06 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 53,812 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0000899243-22-021633 · doc4.xml · derivative · entry 1 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,812 Underlying: Common Stock · 53,812 shares Expires 2032-06-06 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 22:22 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $25.60 | $0.00 |
DisclosureSEC source: 0001209191-21-069798 · doc4.xml · derivative · entry 2 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2022-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 22:22 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 1,500 | $25.60 | $38,400.00 |
DisclosureSEC source: 0001209191-21-069798 · doc4.xml · nonDerivative · entry 1 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2021 Filed Nov 23, 2021 12:46 UTC | MAXCYTE, INC. MXCT · Entity 6608 | PurchaseCommon Stock | 20,000 | $11.12 | $222,400.00 |
DisclosureSEC source: 0001209191-21-066289 · doc4.xml · nonDerivative · entry 1 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · price: The Reporting Person purchased the securities on the open market at purchase prices ranging from $11.01 to $11.16 per share, with a weighted average purchase price of $11.12 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 21:13 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.63 | $0.00 |
DisclosureSEC source: 0001209191-21-050931 · doc4.xml · derivative · entry 1 DOUGLAS RICHARD · CIK 0001021015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-08-09 F1 · derivative.exercise_date: 25% of the shares underlying the option vest on August 9, 2022 and the remaining shares underlying the option vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.